Benjamin T. Dake - Sep 6, 2022 Form 4 Insider Report for Aerovate Therapeutics, Inc. (AVTE)

Role
Officer Title: President, Chief Operating Officer and Secretary
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Stock symbol
AVTE
Transactions as of
Sep 6, 2022
Transactions value $
-$207,093
Form type
4
Date filed
9/8/2022, 05:30 PM
Previous filing
Aug 18, 2022
Next filing
Sep 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $15.9K +9.17K $1.74* 9.17K Sep 6, 2022 Direct F1
transaction AVTE Common Stock Sale -$79.3K -4.42K -48.24% $17.94 4.74K Sep 6, 2022 Direct F1, F2
transaction AVTE Common Stock Sale -$78.5K -4.14K -87.23% $18.98 606 Sep 6, 2022 Direct F1, F3
transaction AVTE Common Stock Sale -$12K -606 -100% $19.78 0 Sep 6, 2022 Direct F1, F4
transaction AVTE Common Stock Options Exercise $14.3K +8.22K $1.74* 8.22K Sep 7, 2022 Direct F1
transaction AVTE Common Stock Sale -$83 -4.56 -0.12% $18.12 3.66K Sep 7, 2022 Direct F1, F5
transaction AVTE Common Stock Sale -$67.4K -3.66K -100% $18.42 0 Sep 7, 2022 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -9.17K -16.81% $0.00 45.3K Sep 6, 2022 Common Stock 9.17K $1.74 Direct F1, F7
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -8.22K -18.13% $0.00 37.1K Sep 7, 2022 Common Stock 8.22K $1.74 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.56 to $18.50, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.57 to $19.50, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.595 to $20.075, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.32 to $18.32, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.345 to $18.625, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F7 A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Officer Title: President, Chief Operating Officer and Secretary